Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
16.06.2015
Vtesse, Inc. Expands Scientific Advisory Board, Fills Key Patient Advocacy Position to Prepare for Further Clinical Development of VTS-270 in Niemann-Pick Disease Type C (NPC)
Gaithersburg, MD, June 15, 2015 – Vtesse, Inc.,  a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced today the expansion of its Scientific Advisory Board (SAB) and the filling of a key staff position in patient advocacy.  
Dato
10.06.2015
Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis
CANTERBURY, UK, 10 JUNE, 2015 -- Ziarco Group Ltd., a biopharmaceutical company focusing on inflammatory skin diseases, today announced that it has dosed the first patient in its Phase 2a proof-of-concept clinical trial of ZPL-389 in patients with moderate to severe atopic dermatitis at MAC Clinical Research in Manchester, UK. ZPL-389 is the Company’s novel, once-daily, oral histamine H4 receptor antagonist for the treatment of inflammatory skin diseases, including atopic dermatitis and psoriasis. 
Dato
10.06.2015
Ziarco Announces Appointment of Dr. Pablo Jimenez as Chief Medical Officer
CANTERBURY, UK, 8 JUNE, 2015 -- Ziarco Group Ltd., a clinical-stage biopharmaceutical company focusing on inflammatory skin diseases, today announced the appointment of Pablo Jimenez, M.D., as Chief Medical Officer, effective immediately. Dr. Jimenez will oversee the clinical development of Ziarco’s programs targeting conditions such as atopic dermatitis and psoriasis.
Dato
08.06.2015
Spero Completes $30 Million Financing

Expands focus on gram-negative bacteria by adding Potentiator program to pipeline of novel antibiotic compounds.

CAMBRIDGE, Mass.– June 8, 2015 –  Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced that the company secured $30M million in a Series A financing.  Lundbeckfond Ventures led the round as a new investor with participation from additional new investors Merck Research Ventures and The Kraft Group. All existing investors participated including Atlas Venture, SR One, and Partners Innovation Fund.  The company also expanded its pipeline of novel anti-infectives through the addition of a Potentiator program targeting Gram-negative infections.  Spero plans to use the proceeds from this financing to advance the potentiator franchise into the clinic by 2016, progress its anti-virulence program in partnership with Roche through the submission of an Investigational New Drug (IND) application, and develop additional programs in its pipeline focused on unmet medical needs in bacterial infections.  

Dato
27.05.2015
CERAMENT™|G SHOWN TO INCREASE BONE FORMATION AND DECREASE INFECTION
Pivotal Rat Study Presented at 2015 Orthopedic Research Society Annual Meeting  

Lund, Sweden, (PRNEWSWIRE) May 27, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a pivotal pre-clinical study of CERAMENT™|G as presented at the 2015 Orthopedic Research Society (ORS) Annual Meeting.  The study assessed the efficacy and safety of CERAMENT™|G, the first injectable gentamicin eluting bone substitute, in the completeness of bone healing after surgery and in the eradication of chronic infection.  Study results demonstrated that CERAMENT™|G increased new bone growth and decreased the rate of infection as compared to treatment without a bone filler and treatment with CERAMENT™|BONE VOIDE FILLER without gentamicin.   

Dato
19.05.2015
K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor
South San Francisco, CA – May 12, 2015 – Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor biology to new therapeutics for retinal disease and cancer, today announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director of the company and will work closely with Iconic’s leadership team as a Senior Scientific Advisor.  Dr. Hirth has over 30 years of biotechnology and pharmaceutical discovery and development experience and currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, and Afferent Pharmaceuticals. 
Dato
19.05.2015
BONESUPPORT EARNS FROST & SULLIVAN’S 2015 BEST PRACTICES AWARD FOR ITS NOVEL PRODUCT, CERAMENT™
Lund, Sweden, (PRNEWSWIRE) May 13, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received the Frost & Sullivan 2015 Growth Capital Investment Award for outstanding achievement and superior performance in the area of technological innovation and strategic product development in the orthopedic biomaterial market with its proprietary product, CERAMENT™. CERAMENT™ is a platform technology currently available under four product lines:  CERAMENT™|G, CERAMENT™|V, CERAMENT™|BONE VOID FILLER and CERAMENT™| SPINE SUPPORT. CERAMENT™|G and CERAMENT™|V are the only approved injectable bone substitutes with antibiotics indicated to promote and protect bone healing in the management of bone infection.
Dato
19.05.2015
PSIOXUS THERAPEUTICS RAISES A £25M SERIES C INVESTMENT TO PROGRESS ONCOLYTIC VIRUS PLUS CHECKPOINT INHIBITOR COMBINATION STUDY IN METASTATIC COLORECTAL CANCER
OXFORD, UK – 19 May 2015 – PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes from the antibody ‘armed’ series of AbEnAd viruses.
Dato
06.05.2015
ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 STUDY WITH APD403 IN CHEMOTHERAPY INDUCED NAUSEA & VOMITING (CINV)

Primary endpoint of preventing delayed CINV met with high significance

Cambridge, UK – 6th May 2015: Acacia Pharma Ltd (“Acacia Pharma” or “the Company”), a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

Dato
30.04.2015
BONESUPPORT ANNOUNCES CE-MARK OF CERAMENT™|V, THE FIRST INJECTABLE VANCOMYCIN ELUTING BONE SUBSTITUTE IN THE MANAGEMENT OF OSTEOMYELITIS
Lund, Sweden, (PRNEWSWIRE) April 29, 2015 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received CE-mark for CERAMENT™|V, the first injectable vancomycin eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.  CERAMENT™|V is an extension of the company’s antibiotic eluting bone substitute portfolio which includes CERAMENT™|G, the first injectable gentamicin eluting bone substitute.  Vancomycin is used to treat gram-positive bacteria that are known to be resistant to most antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA).  The Infectious Disease Society of America recommends vancomycin as first-line therapy for these complicated infections, which include bone, and joint infections. The company is launching CERAMENT™|V immediately in all CE-mark countries.
Forrige Forrige 10 11 12 13 14 15 16 17 18 19 20 Næste 10 Næste